What is the max dose of chloroprocaine?

The maximum dose of 2-chloroprocaine (Nesacaine) is 11 mg/kg without epinephrine (absolute maximum 800 mg) and 14 mg/kg with epinephrine (absolute maximum 1000 mg). For neonates, the recommended dose is 80% of the child dose, approximately 8-10 mg/kg without epinephrine.

Why is chloroprocaine the safest local anesthetic for neonates?

2-Chloroprocaine is the safest local anesthetic for neonates because it is an ester-class agent hydrolyzed by plasma cholinesterase (pseudocholinesterase), which is fully functional at birth. Unlike amide local anesthetics (lidocaine, bupivacaine, ropivacaine) that require hepatic CYP450 metabolism — immature in neonates — chloroprocaine is rapidly broken down in plasma with a half-life of approximately 60 seconds. This ultra-rapid metabolism makes systemic toxicity extremely unlikely, giving it the lowest cardiotoxicity ranking (1 out of 5) among local anesthetics.

What is the half-life of chloroprocaine?

The plasma half-life of 2-chloroprocaine is approximately 60 seconds (~1 minute). This is the shortest half-life of any local anesthetic in clinical use. Chloroprocaine is rapidly hydrolyzed by plasma cholinesterase (pseudocholinesterase), an esterase enzyme present in blood plasma. This ultra-rapid metabolism is the primary reason for its excellent safety profile.

2-Chloroprocaine (Nesacaine) Dosing Guide

Maximum Doses, Pediatric Safety, and Neonatal Pharmacology

Ester-class local anesthetic — lowest cardiotoxicity, safest for neonates

Clinical Decision Support Tool. This page is a reference aid for licensed healthcare professionals. It does not replace clinical judgment. Always verify doses against current guidelines, institutional protocols, and patient-specific factors before administration.

Adult Maximum Doses

Condition	Max Dose (mg/kg)	Absolute Max (mg)
Without epinephrine	11 mg/kg	800 mg
With epinephrine	14 mg/kg	1000 mg

Example: 70 kg Adult

Condition	Calculated Dose	Administered Dose
Without epinephrine	70 × 11 = 770 mg	770 mg (below 800 mg cap)
With epinephrine	70 × 14 = 980 mg	980 mg (below 1000 mg cap)

For obese patients (BMI ≥ 30), use lean body weight (Janmahasatian equation) as the weight basis.

Pediatric Maximum Doses

Age Tier	Without Epi (mg/kg)	With Epi (mg/kg)	Notes
Neonate (<1 month)	8–10 mg/kg	Use with caution	80% of child dose; safest LA for this age
Young infant (1–5 months)	11 mg/kg	14 mg/kg	Esterase metabolism fully functional
Older infant (6–11 months)	11 mg/kg	14 mg/kg	Standard dosing
Child (1–7 years)	11 mg/kg	14 mg/kg	Standard dosing
Adolescent (8+ years)	11 mg/kg	14 mg/kg	Standard dosing; absolute caps apply at higher weights

Always use total body weight (actual weight) for pediatric dosing. Absolute maximum caps (800 mg / 1000 mg) apply when the weight-based calculation exceeds them.

Neonatal Safety Profile

Safest local anesthetic for neonates. 2-Chloroprocaine holds the highest neonatal safety ranking (1 out of 5) among all local anesthetics for three critical reasons:

Plasma cholinesterase is functional at birth. Unlike hepatic CYP450 enzymes (required for amide metabolism), the esterase enzyme that hydrolyzes chloroprocaine is present and active in neonatal plasma from day one.
Ultra-short half-life (~60 seconds). Rapid hydrolysis means the drug is cleared from plasma almost immediately, making toxic accumulation extremely unlikely even with repeated dosing.
Lowest cardiotoxicity (1/5). The combination of rapid metabolism and low intrinsic cardiac sodium channel affinity gives chloroprocaine the best cardiac safety profile of any local anesthetic.

Why Amide Agents Are Riskier in Neonates

Amide local anesthetics (lidocaine, bupivacaine, ropivacaine, mepivacaine) depend on hepatic cytochrome P450 enzymes for metabolism. Neonatal CYP450 activity is approximately one-third of adult levels at birth and does not mature until 6–12 months. This means:

Prolonged plasma half-lives (2–3x adult values)
Risk of drug accumulation with repeat doses or continuous infusions
Increased susceptibility to cardiovascular toxicity

Chloroprocaine bypasses this limitation entirely because its metabolism is independent of hepatic function.

Neonatal Dose Recommendation

Parameter	Value
Recommended dose (no epi)	8–10 mg/kg (80% of child dose)
Cardiotoxicity rank	1/5 (lowest / safest)
Neonatal safety rank	1/5 (best)
Metabolism	Plasma cholinesterase (functional at birth)
Half-life	~60 seconds

Pharmacokinetics

Parameter	Value
Drug class	Ester local anesthetic
Trade name	Nesacaine
Metabolism	Rapid hydrolysis by plasma cholinesterase (pseudocholinesterase)
Plasma half-life	~60 seconds (shortest of all local anesthetics)
Onset	Rapid (6–12 minutes)
Duration	Short (30–60 minutes without epi)
Cardiotoxicity rank	1/5 (lowest)
Primary metabolite	2-Chloro-4-aminobenzoic acid (inactive)

Rapid Hydrolysis

Chloroprocaine is hydrolyzed by plasma cholinesterase (also called pseudocholinesterase or butyrylcholinesterase) at an extremely rapid rate. The enzyme cleaves the ester bond, producing 2-chloro-4-aminobenzoic acid and diethylaminoethanol, both pharmacologically inactive. This mechanism operates entirely in the bloodstream and does not depend on hepatic function, renal function, or any organ-specific clearance pathway.

Cholinesterase deficiency: Patients with atypical pseudocholinesterase (prevalence ~1 in 3,200) or acquired cholinesterase deficiency (severe liver disease, organophosphate exposure, pregnancy) may have prolonged chloroprocaine effect and increased toxicity risk. Screen at-risk patients and consider alternative agents.

Clinical Notes

Ester vs. Amide Classification

Local anesthetics are divided into two classes based on their chemical linkage:

Esters (chloroprocaine, procaine, tetracaine): metabolized by plasma cholinesterase. Cross-allergy with PABA derivatives. Generally shorter duration.
Amides (lidocaine, bupivacaine, ropivacaine, mepivacaine): metabolized by hepatic CYP450 enzymes. Longer duration. No cross-reactivity with esters.

Chloroprocaine is the preferred ester for regional anesthesia due to its rapid onset, predictable duration, and excellent safety profile.

Neonatal Preference

When a local anesthetic is needed for neonatal procedures (caudal blocks, peripheral nerve blocks, wound infiltration), chloroprocaine should be the first-line agent considered. Its independence from hepatic metabolism eliminates the primary pharmacokinetic risk factor in this age group. The trade-off is shorter duration of action compared to amides, which may require repeat dosing or catheter-based techniques for longer procedures.

Short Duration Considerations

The short duration of chloroprocaine (30–60 minutes without epinephrine) is both its primary limitation and its safety advantage. For procedures requiring longer analgesia, consider:

Addition of epinephrine to extend duration
Catheter placement for continuous or repeat bolus dosing
Transition to an amide agent when age-appropriate hepatic metabolism is established (>6 months)

Calculate Safe Doses with MaxLocal

Weight-based dosing with neonatal age tiers, fractional toxicity tracking, and instant LAST protocol access — all offline.

Get MaxLocal on Google Play

Learn more at max-local.app

Related Dosing Guides

References

Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564-575.
Mazoit JX, Dalens BJ. Pharmacokinetics of local anaesthetics in infants and children. Clin Pharmacokinet. 2004;43(1):17-32.
Tobias JD. Caudal epidural block: a review of test dosing and recognition of systemic injection in children. Anesth Analg. 2001;93(5):1156-1161.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third ASRA Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2020;45(4):247-253.
Lerman J, Strong HA, LeDez KM, et al. Effects of age on the serum concentration of alpha 1-acid glycoprotein and the binding of lidocaine in pediatric patients. Clin Pharmacol Ther. 1989;46(2):219-225.

Clinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Always verify information against current guidelines and institutional protocols before clinical use.